Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Avidity Biosciences (NASDAQ:RNA) and maintained a $35 price target for the company's stock.
November 29, 2023 | 9:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Avidity Biosciences and maintained a $35 price target.
The reiteration of a Buy rating by a respected analyst typically instills confidence in investors and can lead to a positive short term impact on the stock price. The maintenance of a $35 price target suggests a significant upside potential from the current trading price, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100